Skip to content
lifestyle.latabloid.com/
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Nuvectis Pharma, Inc.
Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
July 23, 2026
Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
July 23, 2026
Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights
May 21, 2026
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting
March 31, 2026
Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights
February 13, 2026